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SEMAbstract In the present work attempts have been made to prepare the nanostructured lipid carrier
(NLC) gel, by using minoxidil, which is preferably used in case of Alopecia, i.e. baldness pattern as
a effective drug. The nine different formulations of Minoxidil-NLC (NLC1–NLC9) were prepared
using solid and liquid lipids with Cholesterol and Soya lecithin in different concentrations by the
melt dispersion ultrasonication method. Properties of NLC1–NLC9 such as the particle size and
its distribution, the scanning electron microscopy (SEM), the drug entrapment efﬁciency (EE),
and the drug release behavior were investigated. The nanoparticulate dispersion was suitably gelled
and characterized with respect to drug content, pH, spreadability, rheology, and in vitro release.
Safety of the NLC-based gel was assessed using primary skin irritation studies. The formulated
NLC3 was spherical in shape, with average particle size of 280 nm, zeta potential of 42.40 mV
and entrapment efﬁciency of 86.09%. Differential Scanning Calorimeter (DSC) measurements
revealed that imperfect crystallization occurred in the inner core of the NLC particles. The drug
release behavior from the NLC displayed a biphasic drug release pattern with burst release at
the initial stage followed by sustained release. These results indicated that the NLC3 is a suitable
carrier of minoxidil with improved drug loading capacity and controlled drug release properties.
It has been observed that NLC gel produces the gel with good consistency, homogeneity, spread-
ability and rheological behavior. The developed NLC-based gel showed faster onset and elicited
prolonged activity up to 16 h. The present study concluded that the NLC-based gel containing
minoxidil dissolved in a mixture of solid lipid and liquid lipid in the nanoparticulate form helped
us to attain the objective of faster onset yet prolonged action as evident from in vitro release.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Pharmaceutical technology has taken the advantage of the ad-
vent of Nanotechnology; new pharmaceutical dosage forms
are under development to deliver many physicochemically dif-
ferent drug molecules (Hommoss, 2008; Muller and Almeida,
2005). Poor water solubility and insufﬁcient bioavailability of
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fore, there is an increasing need to develop a drug carrier system
that overcomes this drawback (Hommoss, 2008). As a vehicle
for controlled release of active substances and targeting to skin
layers, nanodisperse systems such as Liposomes, nano emul-
sions, and lipid nanoparticles are gainingmore andmore impor-
tance (Utreja and Jain, 2001).
In the beginning of the 1990s, solid lipid nanoparticles
(SLN) were developed as an alternative carrier system to the
existing traditional carriers, such as emulsions, liposomes,
and polymeric nanoparticles (Pardeike et al., 2009; Rajashree
et al., 2011). Compared with the traditional carriers, SLN
are well-tolerated, have high bioavailability, a nice targeting ef-
fect, and can be produced on a large industrial scale. The SLN
features have been considered advantageous for topical admin-
istration of active substances (Uner and Yener, 2007). Poten-
tial problems associated with SLN namely, limited drug
loading, risk of gelation and drug leakage during storage
caused by lipid polymorphism have been further minimized
by a new generation of lipid systems, the nanostructured lipid
carriers (NLC) developed at the turn of the millennium
(Muller et al., 2002a). NLC consists of a mixture of especially
very different lipid molecules, i.e., solid lipid(s) is blended with
liquid lipid(s) (oils). The resulting matrix of the lipid particles
shows a melting point depression compared to the original so-
lid lipid; however, the matrix remains solid at body tempera-
ture (Muller et al., 2000; Saupe et al., 2005). SLN and NLC
are colloidal carrier systems providing controlled release pro-
ﬁles for many substances in tropical route. They are composed
of physiological and biodegradable lipids as a carrier, exhibit-
ing low systemic toxicity and low cytotoxicity (Muller et al.,
1997).
In view of topical administration, these systems possess
occlusive properties because of ﬁlm formation on the skin sur-
face (Wissing and Muller, 2002b). It reduces the transepider-
mal water loss and therefore enhances the penetration of
drugs through the stratum corneum by increased hydration.
It has also been reported that the occlusion factor of SLN
and NLC is related to their particle size, that is, it increases
with the decrease of the mean particle diameter (Wissing and
Muller, 2002a, 2003). The small size of the lipid particles en-
sures close contact with the stratum corneum and can increase
the amount of drug penetrating into the mucosa or skin. Due
to their solid lipid matrix, a controlled release from these car-
riers is possible (Muller et al., 2002a). In addition, by control-
ling the amount of liquid lipids added to the formulation, the
NLC remains in its solid state at body temperature and the
modulation of drug release proﬁle can be achieved. This be-
comes an important tool when it is necessary to supply the
drug over a prolonged period of time, to reduce systemic
absorption, and when drug produces irritation in high concen-
trations (Muller et al., 2000; Chaudhari, 2012).
Minoxidil, a pyridine-derivative, was initially developed as
an oral antihypertensive agent. However, its major clinical
attraction is related to its common side effect on the promo-
tion of hair growth (Atrux-Tallau et al., 2009). Alopecia is a
common form of hair loss in both men and women. Minoxidil
is widely used for the treatment of alopecia (Messenger and
Rundegren, 2004). Commercial products containing minoxidil
are usually solutions with high percentage of ethyl alcoholand/or propylene glycol. Twice-daily applications are recom-
mended as proper use (Wagner and Kenreigh, 2007; Aronson,
2006). However, repeated applications of high ethyl alcohol
and/or propylene glycol content products lead to severe ad-
verse effects such as scalp dryness, irritation, burning, redness
and allergic contact dermatitis. Since most of the products con-
taining minoxidil available on the market consist of ethyl
alcohol–propylene glycol–water solutions, new dermatological
formulations free of organic solvents are needed to minimize
adverse effects and optimize androgenic alopecia treatment
(Padoisa et al., 2011). Hence to minimize the side effects and
to improve the therapeutic efﬁciency of minoxidil, the develop-
ment of new systems for topical delivery of such drug is in
demand.
Therefore, the aim of the present work was to develop the
NLC gel formulation containing minoxidil, using different
concentrations of solid and liquid lipids, to evaluate its physi-
cochemical properties and stability.
2. Materials and methods
Minoxidil, was obtained as gift from Dr. Reddy’s Laboratory,
Hyderabad, India. Tristearin was provided by Glenmark
Generics, Mumbai, India. Oleic acid, Cholesterol and
Tween-80 were purchased from Merck Pvt. Ltd., Mumbai, In-
dia. Soya lecithin (Phosphatidylcholine), Pluronic F-68, Triton
X-100, Carbopol 934 and Triethanolamine were purchased
from Hi-Media Laboratories, Mumbai, India. Chemicals and
reagents were of the highest purity grade commercially avail-
able from Merck Pvt. Ltd., Mumbai, India.
2.1. Preparation of minoxidil loaded NLC
The NLCs were prepared by the melt dispersion ultrasonica-
tion method. The lipid (oleic acid and tristearin), cholesterol
and phosphatidylcholine (soya lecithin) were blended and
melted at 75 C, along with the minoxidil, to form a uniform
and clear oil phase. Meanwhile, the aqueous phase consisting
of dispersing surfactant Tween-80 in double distilled water
was maintained at 75 C. The oil phase was added to the aque-
ous phase, and both phases were mixed by the aid of agitation
at 600 rpm for 10 min at this temperature to form a micro-
emulsion. This warm microemulsion was diluted in cold water
(2–3 C) under mechanical stirring to form NLC dispersion
such that the concentration of minoxidil in the ﬁnal dispersion
remains 2% w/w (Jain et al., 2009; Wang et al., 2010).
2.2. Preparation of gel formulations
The nanoparticulate dispersion obtained after diluting the
warm microemulsion templates was gelled using gelling agents.
Based on the compatibility with nanoparticulate dispersion,
the esthetic appeal and the ease of spreadability carbopol
(2%) was selected as the gelling agent. Carbopol was added
to the nanoparticle dispersion under overhead stirring at
800 rpm (Remi, Mumbai, India). Stirring was continued until
carbopol was dispersed. The carbopol dispersion was neutral-
ized using 0.05% (w/w) Triethanolamine and pH of gel was ad-
justed to 7.4 (Joshi and Patravale, 2006).
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2.3.1. Determination of particle size, polydispersity index and
zeta potential
All measurements were performed in triplicates. The average
particle size and polydispersity index (PI) of NLCs were deter-
mined by Zetasizer Nano ZS (Malvern Instruments, Malvern,
UK) at a temperature of 25 ± 2 C and at 90 to the incident
beam applying the principle of photon correlation spectros-
copy (PCS). Dispersions were diluted with double distilled
water to ensure that the light scattering intensity (between
6e+004 and 1e+006), was within the instrument’s sensitivity
range.
Laser Doppler electrophoresis technique was applied to
measure particle electrostatic charge. The zeta potential was
analyzed by Zetasizer Nano ZS (Malvern Instruments, Mal-
vern, UK) at 25 ± 2 C after appropriate dilution with double
distilled water (Souto and Muller, 2005).
2.3.2. Scanning electron micrographic studies
Images were recorded on a scanning electron micrograph
(magniﬁcation: 50·; accelerating voltage: 15.0 kV). Analysis
was performed at 25 ± 2 C. The NLC dispersion was diluted
appropriately and sonicated. Few drops of the dispersion were
placed on the grid and allowed to dry (Zhao et al., 2010). After
the samples were dried thoroughly, the image was captured
(Fig. 2).
2.3.3. Entrapment efﬁciency
Determination of the amount of drug incorporated in NLC is
of prime importance, since it inﬂuences the release characteris-
tics. The amount of drug encapsulated per unit weight of the
nanoparticles is determined after separation of the free drug
and solid lipids from the aqueous medium. A known dilution
of the NLC dispersion was prepared, and 100 lL was placed
in the upper chamber of a centrifuge tube matched with an
ultraﬁlter and centrifuged for 20 min at 10,000 rpm (Joshi
and Patravale, 2006). The supernatant and the ﬁltrate were di-
luted appropriately and the amount of drug in both the phases
was determined spectrophotometrically at a wavelength of
280 nm. The drug entrapment efﬁciency in the NLCs was cal-
culated by the following equation.
Entrapment Efficiency ð%Þ ¼ fðWinitial drug Wfree drugÞ=Winitial drug g  100
where, Winitial drug is the weight of total drug in NLC, while
Wfree drug the weight of free drug detected in ﬁltrate.
2.3.4. In vitro drug release
In vitro release studies were performed using a modiﬁed Franz
diffusion cell. Dialysis membrane having pore size 2.4 nm and
molecular weight cut-off between 12,000 and 14,000 was used.
The membrane was soaked in double distilled water for 12 h be-
fore mounting in a Franz diffusion cell. About 0.5 g of semisolid
preparation of NLC was applied to the donor compartment,
and the receptor compartment was ﬁlled with phosphate buffer,
pH 7.4 (25 mL). During the experiments, the solution in the
receptor side was maintained at 37 ± 0.5 C and stirred at
800 rpm with Teﬂon-coated magnetic stirring bars (Chen
et al., 2012). At ﬁxed time intervals, 5 mL of the sample was
withdrawn from the receiver compartment through a side tube
and analyzed spectrophotometrically at 280 nm.A graph of % cumulative release against time in hours was
plotted as depicted in Fig. 4. To describe the kinetics of the
drug release from the NLC, mathematical models such as
zero-order, ﬁrst-order, and Higuchi’s were used. The criterion
for selecting the most appropriate model was based on a good-
ness-of-ﬁt test.
2.3.5. Differential scanning calorimetry (DSC) analysis
Thermograms were recorded with DSC (CDR-4P, Shanghai,
China). For DSC measurement, 10 mg of sample was put in
an open aluminum pan, and then heated at the scanning rate
of 10 C/min between 0 and 400 C temperature ranges (Zhao
et al., 2010).
2.4. Characterization of the gel
2.4.1. Determination of drug content, spreadability, and pH
For determination of drug content, about 500 mg of the gel
was weighed in a 100 mL volumetric ﬂask and dissolved in
50 mL of phosphate buffer of pH 7.4. The volumetric ﬂask
was kept for 2 h and shaken well in a shaker to mix it properly.
It was diluted appropriately and analyzed on a Shimadzu UV-
1700 PC UVVIS at a k-max of 280 nm.
The spreadability of the gel was determined using the fol-
lowing technique: 0.5 g of gel was placed within a circle of
1 cm diameter premarked on a glass plate over which a second
glass plate was placed. A weight of 500 g was allowed to rest
on the upper glass plate (Joshi and Patravale, 2006). The in-
crease in the diameter due to spreading of the gels was noted.
The pH of the gel was determined by using a digital pH me-
ter Model EQ 610, standardized using pH 4.0 and 7.0 standard
buffers before use. One gram of gel was dissolved in 100 mL of
distilled water and stored for 2 h (Joshi and Patravale, 2006).
The results of characterization of gel are summarized in
Table 1.
2.4.2. Rheological studies on the gel
Brookeﬁeld Synchro-Lectric Viscometer (Model RVT) with
helipath stand was used for rheological studies. The sample
(30 g) was placed in a beaker and was allowed to equilibrate
for 5 min before measuring the dial reading using T-C spindle
at 0.5, 1, 2.5, and 5 rpm. At each speed, the corresponding dial
reading on the viscometer was noted. The spindle speed was
successively lowered and the corresponding dial reading was
noted. The measurements were carried out in duplicate at
ambient temperature. Direct multiplication of the dial readings
with factors given in the Brookeﬁeld viscometer catalog gave
the viscosity in centipoises (Joshi and Patravale, 2006). The
consistency index and the ﬂow index were calculated from
the Power law equation:
s ¼ Krn
where: s is shear stress; r is shear rate; K is consistency index;
and n is ﬂow index.
Taking log of both sides,
log s ¼ logKþ n log r
Shear stress ðdynes=cm2Þ ¼ Viscosity ðcpsÞ
Rate of shear ðs1Þ
Table 2 Particle size, PDI, zeta potential for F1–F9
formulation.
Minoxidil-NLC Particle size Polydispersity index Zeta potential
NLC1 524.8 0.718 39.20
NLC2 608.6 0.450 15.30
NLC3 280.4 0.367 42.40
NLC4 508.9 0. 486 44.50
NLC5 469.9 0.604 19.47
NLC6 446.2 0.530 32.60
NLC7 997.0 0.604 21.90
NLC8 2163.2 1.000 23.60
NLC9 946.3 0.507 28.80
Table 1 Quantity of raw material as per formulation (in mg).
Ingredient Formulations
NLC1 NLC2 NLC3 NLC4 NLC5 NLC6 NLC7 NLC8 NLC9
Minoxidil 1000 1000 1000 1000 1000 1000 1000 1000 1000
Tristearin 200 200 200 150 150 150 250 250 250
Oleic acid 50 75 100 50 75 100 50 75 100
Cholestrol 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015
Soya Lecithin 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015
Tween-80 2 2 2 2 2 2 2 2 2
Triton-X 100 10 10 10 10 10 10 10 10 10
Pluronic F-68 15 15 15 15 15 15 15 15 15
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The developed formulations were tested for primary skin irri-
tation on albino mice of either sex weighing 20–22 gm. The
hair was removed from the mice 3 days before the experiment.
The animals were divided into two batches and each batch was
again divided into two groups. The gel containing drugs was
used on the test animal. A piece of cotton wool soaked in sat-
urated drug solution was placed on the back of albino mice ta-
ken as control. The animals were treated daily up to 7 days and
ﬁnally the treated skin was examined visually for erythema and
edema (Joshi and Patravale, 2006).
2.5. Statistical analysis
All values obtained were expressed as mean ± standard error
mean (SEM). Statistical comparisons were performed by anal-
ysis of variance and Student’s t test using SAS Version 8.0
software.
3. Results and discussion
3.1. Preparation of NLCs
The Minoxidil-loaded NLCs were prepared using varying con-
centrations of solid lipid and liquid lipid by the melt dispersion
ultrasonication technique. The quantity of ingredient used and
the properties of resultant Minoxidil-loaded NLC are shown in
Tables 1 and 2.
From Table 2, the results demonstrated that on increasing
the concentration of solid lipid, it enhances the size of parti-
cles. However the mixture of tristearin and oleic acid (2:1) de-
creases the particle size up to 280.4 nm in NLC3. Additionally
from the result it has been observed that the mixture of tristea-
rin and oleic acid (10:3) increases the particle size up to
2163.2 nm in NLC8. This result was probably related with
the different viscosities of NLC produced by mixing different
concentrations of tristearin and oleic acid. It indicates that
the higher oleic acid content reduced the viscosity inside
NLC, and consequently, reduced the surface tension to form
smaller and smoother surface particles. On the other hand,
polydispersity is a measure of particle homogeneity and it var-
ies from 0 to 1. The nearer the value of polydispersity to zero,
the higher is the homology between the particles. The polydis-
persity index of NLC3 was 0.367 indicating wide particle size
distributions (Jia et al., 2010). These results suggest that the ra-
tio of tristearin and oleic acid of NLC3 was favored to form
nanoparticles with more homogenous size distributions due
to the size reduction.To determine the long-term physical stability of the colloi-
dal systems, the zeta potential was evaluated. The nanoparticle
emulsion had the higher zeta potential value, indicating the
better stability of this colloidal system of the lipid particles.
This resulted from the electrostatic repulsion, which could pre-
vent the biocolloids from aggregation of nanoparticles of
emulsion. Zeta potential values higher than 30 mV show
good physical stability, being optimized when they reach
approximately 60 mV, exhibiting a very good physical stabil-
ity during the shelf-life. In this study, zeta potential of NLC1
to NLC9 was in the range of 15.30 to 44.50 mV. While
the concentration of oleic acid present in NLC3 is appropriate
it brings the zeta potential up to 42.40 mV, demonstrating
that NLC3 should possess a good physical stability since par-
ticle aggregation is not likely to occur owing to electrostatic
repulsion. Additionally the coating of hydrophilic Tween 80
could further improve the stability of the lipid present in
NLC by hydration in the surface layer (Teeranachaideekul
et al., 2007; Lim and Kim, 2002).
3.2. Scanning electron microscopy (SEM)
To obtain more information about the particle size and shape,
SEM analysis was also performed. The micrograph of the
NLC3 illustrated spherical droplets in the nanometer range
(Fig. 1) which was in agreement with the size data determined
by PCS. The results indicated that the particles were spherical
and no drug crystal of particles visible in the ﬁgure. The picture
shows agglomeration of particles due to the lipid nature of the
carriers and sample preparation prior to SEM analysis. Some
particle shapes deviating from sphericity might be due to the li-
pid modiﬁcation during the drying process of sample treatment.
Figure 1 Scanning electron microscopy of NLC.
Figure 2 Percentage entrapment efﬁciency for minoxidil-NLC.
Each value represents the mean ± SD (n = 3).
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pid. Highly pure tristearin particles are more cuboid (Liu
et al., 2007).
3.3. Entrapment efﬁciency
The percentage of incorporated drug in the lipid matrix
(entrapment efﬁciency) was evaluated. Fig. 2 depicted the high
amount of drug entrapment efﬁciency in the NLC3 was found
to be 86.09%, probably because of its lipophilic character. The
NLC3 is responsible for higher entrapment efﬁciency in com-
parison with other NLC formulation. This result is due to the
binary mixture of liquid and solid lipids, resulting in only a very
weak crystallization. The NLC4 indicated the low drug entrap-
ment efﬁciency, i.e. 29.68% is mainly due to the partitioning of
the drug between the oil phase and the aqueous phase.
The NLC3 and NLC6 have the same amount of lipid ma-
trix but both formulations produce different drug entrapment
efﬁciency. The drug entrapment efﬁciency in NLC3 and NLC6
were found to be 86.09% and 52.28%, respectively. The
change in drug entrapment efﬁciency of both formulations
could be due to the different ratio of solid lipid and liquid lipid
present in the mixture. NLC8 and NLC9 have a higher amount
of lipid as compared to all other formulations but the entrap-
ment efﬁciency was low. Hence it conﬁrms that maximum
entrapment efﬁciency of drug in the lipid matrix depends on
the optimum ratio of solid lipid and liquid lipid mixture. Here
NLC3 showed maximum drug entrapment efﬁciency so that it
was selected for in vitro drug release study.
3.4. Assessment of drug release
To elucidate the mechanism of drug release from NLC for top-
ical administration, in vitro release studies using vertical Franz
diffusion cells have been performed for NLC3 and temperature
maintained at 32 C. In vitro release curves of NLC3 type
drug-loaded nanoparticles are shown in Fig. 3. For NLC3 for-
mulation, a biphasic drug release pattern was observed, that
was drug burst release at the initial stage and followed by sus-
tained release at a constant rate. This phenomenon might be
explained in two aspects, i.e. higher oleic acid content andsmaller size of nanoparticles. Firstly, the obtained nanoparti-
cles were prepared by the method of melt dispersion ultrason-
ication at a high temperature and solidiﬁcation at a low
temperature. During the solidiﬁcation at a low temperature,
due to the solid lipid (tristearin) owning a higher melting point,
it would rapidly solidify to form a solid lipid core in which li-
quid lipid was randomly distributed. When the liquid lipid
(oleic acid) content is higher, liquid lipids would be located
at the outer shell of the nanoparticles besides being distributed
in the solid lipid core, which led to drug-enriched shell related
with drug burst release at the initial stage (Jia et al., 2010; Hu
et al., 2005). In addition, as liquid lipid was distributed in solid
lipid, the crystalline structure of NLC became more imperfect
and allowed drugs loaded to release more easily, thus increas-
ing the rate of drug release. Secondly, it was of smaller size.
When the particle size decreased, the speciﬁc surface area of
nanoparticles increased, therefore, the release rate became fast.
Therefore, the fastest release rate in the initial stage, emerged
in the nanoparticles of NLC3, resulted from both the smaller
size and higher oleic acid content.
3.5. DSC
DSC gives the information regarding the crystalline or amor-
phous nature of the drug using the fact that different lipid
modiﬁcations possess different melting points. The DSC ther-
mograms of minoxidil, tristearin, mixture of tristearin and
oleic acid (2:1) and ternary bulk mixture of minoxidil, tristea-
rin and oleic acid (2:1) are shown in Fig. 4d. The minoxidil and
tristearin illustrated an endothermic peak at 248.5 and 68.6 C
(Fig. 4a and b). The bulk mixture of tristearin and oleic acid
exhibited an endothermic peak at 65.1 C (Fig. 4c) with a wid-
ening of melting peak which indicates that oleic acid is dis-
solved in tristearin, inducing a less pronounced crystalline
structure. From the ﬁgure, the ternary mixture of minoxidil,
tristearin and oleic acid in the ratio used in minoxidil loaded
NLC was investigated in order to obtain information about
the ability of the lipid matrix to dissolve minoxidil. This mix-
ture does not produce any endothermic peak for minoxidil
incorporated in NLC. It has been reported that when the drug
does not show its endothermic peak in the nanoparticulate for-
mulations, it is said to be in the amorphous state (Liu et al.,
2007; Sarmento et al., 2006). Hence, it could be concluded that
the drug was present in the amorphous phase and may have
been homogeneously dispersed in the NLCs.
Figure 3 In vitro release proﬁle of Minoxidil from NLC. Each
value represents the mean ± SD (n = 3).
Figure 5 In vitro release proﬁle of Minoxidil from NLC-Gel.
Each value represents the mean ± SD (n = 3).
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The average particle size of the NLC3 dispersion was esti-
mated to be 280.4 nm with a polydispersity index of 0.367 indi-
cating wide particle size distributions. Polydispersity is a
measure of particle homogeneity and it varies from 0 to 1.
The drug encapsulation efﬁciency within the NLC3 was found
to be 35% and comparatively it was maximum than other for-
mulations. The evaluation study of Minoxidil-loaded NLC3
exhibited good result as compared to all other formulations.
Hence, NLC3 was selected for preparation of gel by using
the gelling agent carbopol 934. The NLC gel showed an opti-
mum viscosity at the concentration of 2% of carbopol 934.
The drug content of the NLC based gel was found to be
89.80 ± 0.82% and pH was found to be 7.29 ± 0.18, which
are within the acceptable limits. Spreadability is an important
property of topical formulation from a patient’s compliance
point of view. Application of the formulation to inﬂamed skin
is more comfortable if the base spreads easily, exhibiting max-
imum slip and drag. The prepared gel produces excellent
spreadability. In general, the gels that possess a high consis-
tency index are less spreadable. The release of the drug from
the formulation is governed by its components as well as by
the consistency of the formulation. Viscosity of the NLC gel
was found to be 32,540 ± 7.63 cps at 5 rpm. It is essentialFigure 4 DSC image of Minoxidil-NLC and its ingredients. (a)
Minoxidil; (b) tristearin; (c) mixture of tristearin and oleic acid; (d)
mixture of minoxidil, tristearin and oleic acid.for any formulation to study its rheological behavior to be
used for topical drug delivery applications. It is important
for its efﬁcacy in delivering molecules onto or across the skin.
Consistency index is a measure of consistency and is equivalent
to apparent viscosity at a shear rate of 1 s1. The consistency
index of the formulation was found to be 10,103. The ﬂow in-
dex n is a measure of the deviation of a system from Newto-
nian behavior (n= 1). A value of n< 1 indicates
pseudoplastic ﬂow or shear thinning; n> 1 indicates dilatant
or shear thickening ﬂow. The gel showed a ﬂow index of
0.361, indicating the pseudoplastic ﬂow behavior. Flow index
reﬂects the mobility of the gel from the container.
3.7. In vitro drug release studies of NLC gel
The study of drug release from gel is an important step in the
development stages of new formulations, as well as a routine
quality-control test for assuring uniformity of the ﬁnished
product. In the in vitro release studies the NLC gel (Fig. 5)
showed burst release in the ﬁrst one hour followed by a steady
release. This could be due to the diffusion of unencapsulated
drug in the ﬁrst hour followed by diffusion from the NLC sur-
face and thereafter from the core. As can be seen in Fig. 4,
92.18% of drug encapsulated within the core of NLC was re-
leased. Burst release as well as sustained release both are of
interest for dermal application. Burst release can be useful to
improve the penetration of drug. Sustained release applied
the drug over a prolonged period of time.
The release data from NLC gel were ﬁtted to the different
models. The value of r2 was found to be highest for the Higu-
chi model (r2 = 0.99). This indicates that the test product fol-
lows matrix diffusion based release kinetics.
4. Conclusion
The Minoxidil-loaded NLCs were prepared using different
concentrations of solid lipid and liquid lipid by the melt disper-
sion ultrasonication technique. NLC3 exhibited a good physi-
cal stability indicated by zeta potential value and a high
entrapment efﬁciency value. The drug release behavior from
the NLC displayed a biphasic drug release pattern with burst
release at the initial stage followed by sustained release. These
results indicated that the NLC3 is a suitable carrier of minox-
idil with improved drug loading capacity and controlled drug
release properties.
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taining minoxidil was formulated by using the gelling agent
carbopol 934. It has been observed that NLC gel produces
the gel with good consistency, homogeneity, spreadabiliity
and rheological behavior. It was found that NLC gel showed
a biphasic release pattern, and provided a fast release initially
for skin saturation followed by a slow and prolonged release
proﬁle to maintain the skin concentration.
The present study concluded that the NLC-based gel con-
taining minoxidil dissolved in a mixture of solid lipid and li-
quid lipid in the nanoparticulate form helped us to attain the
objective of faster onset yet prolonged action as evident from
in vitro release.Acknowledgments
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